Compare Sana Biotechnology Inc (SANA) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Yum China Holdings Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Yum China Holdings Inc trades at $42.55 (market cap $14.74B). The key difference: Yum China Holdings Inc is far larger — about 14.3× Sana Biotechnology Inc's market cap, and Yum China Holdings Inc pays a 2.68% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | YUMC | |
|---|---|---|
Market Cap | $1.03B | $14.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $57.95 |
52-Week Low | $2.68 | $40.18 |
Enterprise Value | $946.04M | $15.65B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
YUMC trades at $43.34, down 0.6% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $0.70 surpassing the $0.67 estimate. Revenue grew to $11.80 billion in 2025, and net income reached $929 million. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of the Pizza Hut Burger Bar to 300 locations.
The outlook remains positive given strong analyst support, with 14 buy ratings and a consensus pointing to 25.6% upside. Key risks include execution of expansion plans and macroeconomic pressures in China. The stock presents a value opportunity with a P/E of 15.88 and solid profitability metrics, but investors should monitor competitive dynamics and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
